A phase Ib trial investigating huperzine-A in (BIS-001) in patients with refractory epilepsy

Trial Profile

A phase Ib trial investigating huperzine-A in (BIS-001) in patients with refractory epilepsy

Planning
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs Huperzine A (Primary)
  • Indications Complex partial epilepsy
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 09 May 2017 According to Biscayne Pharmaceuticals media release, the company reported that the Australian regulatory authorities have cleared Biscayne to begin a Phase 1b trial of BIS-001 at the Royal Melbourne Hospital, enrollment is expected to commence in the coming weeks.
    • 24 Oct 2016 According to Biscayne Pharmaceuticals media release, company expects to advance this study in mid-2017.
    • 28 Jun 2016 According to Biscayne Pharmaceuticals media release, company plans to initiate this study later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top